GANX

Gain Therapeutics, Inc. Common Stock

2.30

USD

GANX Earnings Reports

Positive Surprise Ratio

GANX beat 10 of 19 last estimates.

53%

Next Report

Date of Next Report

Mar 25, 2026

Estimate for Q4 25 (Revenue/ EPS)

-$0.14

Implied change from Q3 25 (Revenue/ EPS)

-6.67%

Implied change from Q4 24 (Revenue/ EPS)

+27.27%

Gain Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 12, 2025, GANX reported earnings of -0.15 USD per share (EPS) for Q3 25, beating the estimate of -0.15 USD, resulting in a 1.96% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +10.07% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 7 analysts forecast an EPS of -0.14 USD, with revenue projected to reach -- USD, implying an decrease of -6.67% EPS, and increase of 0.00% in Revenue from the last quarter.

FAQ

What were Gain Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Gain Therapeutics, Inc. Common Stock reported EPS of -$0.15, beating estimates by 1.96%, and revenue of $0.00, 0% as expectations.

How did the market react to Gain Therapeutics, Inc. Common Stock's Q3 2025 earnings?

The stock price moved up 10.07%, changed from $2.68 before the earnings release to $2.95 the day after.

When is Gain Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 25, 2026.

What are the forecasts for Gain Therapeutics, Inc. Common Stock's next earnings report?

Based on 7 analysts, Gain Therapeutics, Inc. Common Stock is expected to report EPS of -$0.14 and revenue of -- for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.